Articles

At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. Read More ›

Resistance Mechanisms and Adverse Events Associated with Targeted Therapy in Cholangiocarcinoma

By Erin Burns, PhD

Cholangiocarcinoma

TON - April 2022 Vol 15, No 2

Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit. Read More ›

Financial Toxicity in Patients with Cholangiocarcinoma

Cholangiocarcinoma

TON - April 2022 Vol 15, No 2

Data related to health-related quality of life (QOL), including financial toxicity, for patients with cholangiocarcinoma (CCA) who are receiving targeted therapies are limited. Read More ›

Analysis of Healthcare Claims Provides Valuable Insights on the Use of Trastuzumab Biosimilars

By Charlie Dawson

Biosimilars

TON - April 2022 Vol 15, No 2

The development of biosimilar medicines has provided an opportunity for patient utilization of oncology treatments at a lower cost, particularly in individuals for whom biologicals play a predominant role in providing effective therapeutic and supportive care. Read More ›

Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes

Multiple Myeloma

Supplements

IWTI Multiple Myeloma

Exploring the Barriers to Treatment Adherence for Patients with Multiple Myeloma

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Interview with the Innovators

Videos

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss the multiple potential barriers to treatment adherence that some patients with multiple myeloma may face in their cancer journey. Read More ›

IWTI Multiple Myeloma

Helping Patients Prepare for the Setbacks in Their Multiple Myeloma Journey

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Interview with the Innovators

Videos

Relapsing during therapy is devastating for patients with cancer. Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, share their best practices for how to interact with patients who will have many questions about what it means for them and what therapy options are next. Read More ›

Next-Generation Sequencing in Lung Cancer Found to Be Accurate and Cost-Effective

Lung Cancer

Web Exclusives

Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost. Read More ›

Immune Checkpoint Inhibitors May Have Limited Efficacy in Patients with NSCLC with Poor Performance Status

Lung Cancer

Web Exclusives

A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status. Read More ›

Time to Treatment Impacts on Early-Stage Lung Cancer Surgery Outcomes

Lung Cancer

Web Exclusives

Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer. Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 43 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

We Value Your Feedback! Tell Us How You Consume Content